Chemicals & Biochemicals

Emodin

NEW
Emodin

Article No

AG-CN2-0457-M050

Size

50 mg

Source / Host

plant

Shipping Information

Ambient

Product insert

Specifications

CAS No 518-82-1
MW 270.2
Article No AG-CN2-0457-M050
Country Availability DK, EE, FI, IS, LT, LV, NO, SE
Description Emodin
Supplier Adipogen Life Sciences
Format Powder
Notes p56lck protein kinase inhibitor. Competitive casein kinase II (CK2) inhibitor. Anticancer agent with apoptosis inducing with antiangiogenic activity. Antioxidant, vasorelaxant and neuroprotective agent. NF-kappaB activation inhibitor. Inflammasome inhibitor. Potent selective 11beta-HSD1 inhibitor. Improves insulin sensitivity and lipid metabolism. Estrogen receptor ERalpha and ERbeta inhibitor. Inhibits androgen receptor (AR) nuclear translocation and induces AR degradation. VEGFR2, FGFR-1, EGFR, PDGFR-beta and Kit inhibitor. JAK2 inhibitor. Anti-diabetic agent. AMPK activator and PPARgamma agonist. Adipogenesis inhibitor. P2X7 receptor antagonist. Wnt signaling & PI3K/Akt/GSK-3beta pathway modulator.
Molecular Formula C15H10O5
Alias Names Emodol; Frangulic acid; Archin; NSC 622947; NSC 408120; 1,3,8-Trihydroxy-6-methylanthraquinone; Schuttgelb
Product Type Chemicals & Biochemicals
Purity >98%
References Vasorelaxant effect of emodin, an anthraquinone from a Chinese herb: H.C. Huang, et al.; Eur. J. Pharmacol. 205, 289 (1991) | Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum: H. Jayasuriya, et al.; J. Nat. Prod. 55, 696 (1992) | Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-kappaB activation, IkappaB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells: A. Kumar, et al.; Oncogene 17, 913 (1998) | Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor: H. Yim, et al.; Planta Med. 65, 9 (1999) | Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity: H. Matsuda, et al.; Bioorg. Med. Chem. Lett. 11, 1839 (2001) | Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9: G. Srinivas, et al.; Eur. J. Pharmacol. 473, 117 (2003) | Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth: T.L. Cha, et al.; Cancer Res. 65, 2287 (2005) | Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation: H.J. Kwak, et al.; Int. J. Cancer 118, 2711 (2006) | Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor: A. Muto, et al.; Mol. Cancer Ther. 6, 987 (2007) | Screening of Kit inhibitors: suppression of Kit signaling and melanogenesis by emodin: S.J. Lee, et al.; Phytother. Res. 24, 308 (2010) | Neuroprotective effects of emodin in rat cortical neurons against beta-amyloid-induced neurotoxicity: T. Liu, et al.; Brain Res. 1347, 149 (2010) | Inhibition of ATP-induced macrophage death by emodin via antagonizing P2X7 receptor: L. Liu, et al.; Eur. J. Pharmacol. 640, 15 (2010) | Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice: Y. Feng, et al.; Br. J. Pharmacol. 161, 113 (2010) | Promotion of adiponectin multimerization by emodin: a novel AMPK activator with PPARgamma-agonist activity: Z. Chen, et al.; J. Cell Biochem. 113, 3547 (2012) | Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis: S.Z. Lin, et al.; PLoS One 7, e42146 (2012) | The distinct mechanisms of the antitumor activity of emodin in different types of cancer: W.T. Wei, et al.; Oncol. Rep. 30, 2555 (2013) (Review) | Emodin suppresses Wnt signaling in human colorectal cancer cells SW480 and SW620: T. Pooja & D. Karunagaran; Eur. J. Pharmacol. 742, 55 (2014) | Emodin induces neurite outgrowth through PI3K/Akt/GSK-3beta-mediated signaling pathways in Neuro2a cells: S.J. Park, et al.; Neurosci. Lett. 588, 101 (2015) | Anti-Inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation: J.W. Han, et al.; Int. J. Mol. Sci. 16, 8102 (2015)
Research Area Metabolism
Shipping Information Ambient
Size 50 mg
Solubility Soluble in DMSO or 100% ethanol. Insoluble in water.
Source / Host plant
Stability Stable for at least 2 years after receipt when stored at +4°C.
Storage +4°C
Technical Specifications Chemical. CAS: 518-82-1. Formula: C15H10O5. MW: 270.2. Isolated from Polygonum cuspidatum. p56lck protein kinase inhibitor. Competitive casein kinase II (CK2) inhibitor. Anticancer agent with apoptosis inducing with antiangiogenic activity. Antioxidant, vasorelaxant and neuroprotective agent. NF-kappaB activation inhibitor. Inflammasome inhibitor. Potent selective 11beta-HSD1 inhibitor. Improves insulin sensitivity and lipid metabolism. Estrogen receptor ERalpha and ERbeta inhibitor. Inhibits androgen receptor (AR) nuclear translocation and induces AR degradation. VEGFR2, FGFR-1, EGFR, PDGFR-beta and Kit inhibitor. JAK2 inhibitor. Anti-diabetic agent. AMPK activator and PPARgamma agonist. Adipogenesis inhibitor. P2X7 receptor antagonist. Wnt signaling & PI3K/Akt/GSK-3beta pathway modulator.
Product Page Updated 2019-07-12T09:17:06.689Z

Shipping info

The delivery time for this item is approximately 5-8 business days. 
If other deviations occur, this will be noted on the order confirmation or communicated via email.
Please note, we do reserve the right to select the best packaging and shipping method in order to insure the stability of the product and allow efficient order tracking.